Basilea seen up after raising 2026 guidance

By Reuters News

** Shares in Basilea BSLN.S are seen up 7% in pre-market indications after the Swiss biotech company raised its 2026 revenue and operating profit guidance

** The company now expects operating profit of CHF 115 mln (€124 mln), up from CHF 70 mln previously, and revenue of about CHF 310 mln

** Basilea also raised its cash flow target for 2026-2030 and its 2030 financial targets

** Up to the previous session's close, the stock was up 26%​ YTD

(1 euro = 0.9248 Swiss francs)

Capital Com is an execution-only service provider. The present material must be regarded as marketing communication and should not be interpreted as investment research or investment advice. Any opinion that may be provided on this page does not constitute a recommendation by Capital Com or its agents. We do not make any representations or warranty on the accuracy or completeness of the information that is provided on this page. If you rely on the information on this page, then you do so entirely at your own risk